Syndax announces new data from secondary analysis of the pivotal agave-201 trial of niktimvo™ (axatilimab-csfr) in chronic graft-versus-host disease to be presented at 66th ash annual meeting

– rapid responses and symptom improvement observed in inflammatory and fibrotic manifestations of chronic gvhd in heavily pretreated patients – waltham, mass. , nov. 5, 2024 /prnewswire/ -- syndax pharmaceuticals (nasdaq:sndx), today announced that multiple abstracts evaluating niktimvo™ (axatilimab-csfr), an anti-csf-1r antibody for the treatment of chronic graft-versus-host disease (gvhd), have been accepted for presentation at the 66th american society of hematology (ash) annual meeting being held in san diego, california, december 7-10, 2024.
ASH Ratings Summary
ASH Quant Ranking